Spyre Therapeutics, Inc. (SYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$86.93-4.25%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Spyre is advancing its Phase 2 SKYLINE trial for SPY001. It has $741 million in cash as of March 2026. The company aims to pioneer long-acting antibodies for inflammatory bowel disease. These efforts could lead to future growth.
Spyre is losing money and had a $69 million net loss in Q1 2026. Cash from operations was negative $57 million in Q1. The company faces financial strain and uncertain progress on its drug trials.
The price is about 4% below our fair value near $98. The market expects continued losses and no revenue growth soon.
Breaks if: Trial progress stalls or is delayed beyond 2026-Q4
Breaks if: Cash falls below $700 million before 2026-Q4
Losses worsen beyond $69 million and cash flow below -$57 million in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, focusing on the potential of SYRE's clinical trials and product development in the healthcare sector. The current thesis state is mixed, with some positive developments but also notable risks.
The market appears to have a low fragility tier, indicating that there are no immediate concerns affecting the stock's stability. However, SYRE trades at a premium compared to its peers, suggesting that expectations for future performance are elevated.
Management is on track with advancing key clinical trials, which is a positive sign for future growth. However, the recent mixed financial performance and the potential for earnings misses could create volatility in the near term.
The long-term thesis hinges on the outcomes of ongoing clinical trials and the broader healthcare sector's performance. Additionally, any negative guidance or worsening economic indicators could impact SYRE's trajectory significantly.
The most important moves since the prior daily snapshot.
risk label changed from 'moderate' to 'elevated'.
Yes, our read has weakened. The latest earnings beat provided some support for the thesis. However, a sharp drop in the stock price suggests a potential repricing of the thesis. Concerns over mixed trial results for SPY072 in arthritis also pose a threat to the outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, SYRE's performance will depend on its clinical advancements and external market conditions. Not investment advice.